Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
New Strong Sell Stocks for May 29th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for May 22nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
New Strong Sell Stocks for May 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3%
by Zacks Equity Research
Mallinckrodt PLC (MNK) shares rose more than 15% in the last trading session, amid huge volumes.
Key Factors to Influence Penumbra's (PEN) Earnings in Q4
by Zacks Equity Research
Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.
What's in Store for Veeva Systems (VEEV) in Q4 Earnings?
by Zacks Equity Research
Consistent focus on Subscription Services is likely to drive Veeva Systems (VEEV) in Q4.
Is a Beat in Store for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.
Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?
by Zacks Equity Research
Express Scripts (ESRX) expects Q4 results to show earnings growth on strength in PBM segment.
Abiomed's Extended FDA Nod for Impella Boosts Women Health
by Zacks Equity Research
Abiomed (ABMD) boosts cardiomyopathy treatment with the extended FDA nod for Impella. This parallelly bolsters women's cardiac treatment.
CVS Health (CVS) Plans to Boost Hourly Minimum Wage Rate
by Zacks Equity Research
CVS Health (CVS) raises minimum wage level on benefits earned from tax savings. The company plans to put the remaining savings back into the business.
5 Reasons to Invest in PerkinElmer (PKI) Stock Right Now
by Zacks Equity Research
PerkinElmer (PKI) rides on synergies from the acquisition of EUROIMMUN and broadened product base.
Will Global Industrial Unit Aid Ecolab (ECL) in Q4 Earnings?
by Zacks Equity Research
Ecolab's (ECL) strong segmental sales and acquisition-driven strategies are likely to drive fourth-quarter results.
Henry Schein (HSIC) Q4 Earnings to Show Growth in All Lines?
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q4.
AmerisourceBergen (ABC) Gains on World Courier Unit Strength
by Zacks Equity Research
AmerisourceBergen's (ABC) World Courier business gets GDP designation.
Can Pharmacy Services Drive CVS Health's (CVS) Q4 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Q4 earnings are expected to gain from strength in the Pharmacy Services segment.
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.
Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?
by Zacks Equity Research
Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.
Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?
by Zacks Equity Research
Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.
Amphastar (AMPH) in Focus: Stock Moves 9.7% Higher
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) was a big mover last session, as the company saw its shares rise almost 10% on the day.
Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
by Arpita Dutt
Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.
Amphastar Stock Down on CRL for Asthma Drug in the U.S.
by Zacks Equity Research
Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).